Acrivon Therapeutics (ACRV) to Release Earnings on Thursday

Acrivon Therapeutics (NASDAQ:ACRV) will likely be posting its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Acrivon Therapeutics to post earnings of ($0.66) per share for the quarter.

Acrivon Therapeutics Trading Up 4.7 %

Shares of NASDAQ ACRV opened at $5.61 on Tuesday. The firm has a market capitalization of $174.67 million, a price-to-earnings ratio of -2.08 and a beta of 0.85. Acrivon Therapeutics has a one year low of $4.69 and a one year high of $11.90. The business has a fifty day simple moving average of $5.54 and a 200 day simple moving average of $6.65.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ACRV. Cantor Fitzgerald started coverage on shares of Acrivon Therapeutics in a report on Friday, January 31st. They set an “overweight” rating for the company. KeyCorp started coverage on shares of Acrivon Therapeutics in a research note on Friday, January 31st. They set an “overweight” rating for the company. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $23.67.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.